BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38350047)

  • 21. Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma.
    Kim HS; Ku JH; Jeong CW; Kwak C; Kim HH
    World J Urol; 2016 Jun; 34(6):859-69. PubMed ID: 26497823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.
    Abufaraj M; Kimura S; Haitel A; Iwata T; Isleem U; D'Andrea D; Soria F; Mori K; Rink M; Bensalah K; Rouprêt M; Margulis V; Briganti A; Karakiewicz PI; Shariat SF
    Urol Oncol; 2020 Aug; 38(8):685.e17-685.e25. PubMed ID: 32381392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
    Hellenthal NJ; Shariat SF; Margulis V; Karakiewicz PI; Roscigno M; Bolenz C; Remzi M; Weizer A; Zigeuner R; Bensalah K; Ng CK; Raman JD; Kikuchi E; Montorsi F; Oya M; Wood CG; Fernandez M; Evans CP; Koppie TM
    J Urol; 2009 Sep; 182(3):900-6. PubMed ID: 19616245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
    J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
    Matsunaga T; Komura K; Hashimoto T; Muraoka R; Satake N; Tsutsumi T; Tsujino T; Yoshikawa Y; Takai T; Minami K; Taniguchi K; Tanaka T; Uehara H; Hirano H; Nomi H; Ibuki N; Takahara K; Inamoto T; Ohno Y; Azuma H
    World J Urol; 2020 Dec; 38(12):3183-3190. PubMed ID: 32065276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
    Song W; Jeong JY; Jeon HG; Seo SI; Jeon SS; Choi HY; Lee HM; Sung HH
    Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
    Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lymph node dissection on stage-specific survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy.
    Zhai TS; Jin L; Zhou Z; Liu X; Liu H; Chen W; Lu JY; Yao XD; Feng LM; Ye L
    BMC Cancer; 2019 Dec; 19(1):1207. PubMed ID: 31830927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
    Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
    Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Treatments for Advanced Stage, Non-metastatic Upper Tract Urothelial Carcinoma: A Multicenter Study.
    Kim M; Kim JK; Lee J; Kim YS; Lee JL; Kwak C; Jeong CW; Byun SS; Lee SC; Ohyama C; Arai Y; Ahn H
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):819-827. PubMed ID: 30922943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
    Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma.
    Abdul-Muhsin H; De Lucia N; Singh V; Faraj K; Rose K; Cha S; Zhang N; Judge N; Navaratnam A; Tyson M; Ho T; Jacobsohn K; Castle E
    Urol Oncol; 2021 Feb; 39(2):133.e9-133.e16. PubMed ID: 33069555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
    Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
    Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
    Li H; Zhou J; Chen R; Zhu J; Wang J; Wen R
    Urol Oncol; 2023 Aug; 41(8):356.e1-356.e9. PubMed ID: 37331821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
    Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK
    Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
    Metcalfe M; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
    J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
    Shirotake S; Kikuchi E; Tanaka N; Matsumoto K; Miyazaki Y; Kobayashi H; Ide H; Obata J; Hoshino K; Kaneko G; Hagiwara M; Kosaka T; Kanao K; Kodaira K; Hara S; Oyama M; Momma T; Miyajima A; Nakagawa K; Hasegawa S; Nakajima Y; Oya M
    J Urol; 2015 Apr; 193(4):1122-8. PubMed ID: 25444957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma.
    Kim SH; Song MK; Joung JY; Chung J; Lee KH; Seo HK
    Investig Clin Urol; 2019 Nov; 60(6):432-442. PubMed ID: 31692890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
    Czito B; Zietman A; Kaufman D; Skowronski U; Shipley W
    J Urol; 2004 Oct; 172(4 Pt 1):1271-5. PubMed ID: 15371822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.